<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04309981</url>
  </required_header>
  <id_info>
    <org_study_id>CARTBCMA-HCB-01</org_study_id>
    <secondary_id>2019-001472-11</secondary_id>
    <nct_id>NCT04309981</nct_id>
  </id_info>
  <brief_title>Clinical Trial Using Humanized CART Directed Against BCMA (ARI0002h) in Patients With Relapsed/Refractory Multiple Myeloma to Proteasome Inhibitors, Immunomodulators and Anti-CD38 Antibody.</brief_title>
  <official_title>Pilot Study of the Infusion of Differentiated Autologous T-cells From Peripheral Blood, Expanded and Transduced With a Lentivirus to Express a Chimeric Antigen Receptor With Anti-BCMA (TNFRSF17) Specificity Humanized Conjugated With the Co-stimulatory Region 4-1BB and Signal-transduction CD3z (ARI0002h) in Patients With Relapsed/Refractory Multiple Myeloma With Previous Treatment With Proteasome Inhibitor, Immunomodulatory Drug and Anti-CD38 Monoclonal Antibody</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sara V. Latorre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fondos ARI (Assistencia Recerca Intensiva)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto de Salud Carlos III</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fondo Social La Caixa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut d'Investigacions Biom√®diques August Pi i Sunyer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the safety and efficacy of CARTBCMA ARI0002h in patients with relapsed/refractory
      multiple myeloma who have received treatment with proteasome inhibitor, immunomodulatory drug
      and anti-CD38 monoclonal antibody.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 27, 2020</start_date>
  <completion_date type="Anticipated">April 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cytokine release syndrome rate</measure>
    <time_frame>within 30 days of first infusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of the response</measure>
    <time_frame>up to 36 months after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>over the first year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete response rate (CR)</measure>
    <time_frame>at month 3 and month 6 of first infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>at month 6 of first infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to complete response</measure>
    <time_frame>up to 36 months after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate of extramedullary disease by PET-CT</measure>
    <time_frame>up to 36 months after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Negative MRD rate in bone marrow</measure>
    <time_frame>at month 3 and month 6 of first infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate of extramedullary disease by PET-TC</measure>
    <time_frame>at month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>at month 12, and up to 36 months after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) defined as the time elapsed between the infusion of ARI0002h and the death of the patient from any cause</measure>
    <time_frame>up to 36 months after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of tumor lysis syndrome</measure>
    <time_frame>up to 36 months after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of cytokine release syndrome</measure>
    <time_frame>up to 36 months after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of neurological toxicity</measure>
    <time_frame>up to 36 months after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of prolonged cytopenia</measure>
    <time_frame>up to 36 months after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persistence of CART BCMA ARI0002 in peripheral blood</measure>
    <time_frame>month 1, 2, 3, 4, 5, 6 and every 6 months until 2 years of follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expression of BCMA</measure>
    <time_frame>at screening, at day +28, at day +100, at month 6, 12, 18 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of soluble BCMA in serum</measure>
    <time_frame>at screening, at day 0, +3, +7,+14,+28, +70 +100, at month 4, 5, 6, 7, 8, 9, 1,11, 12, 18 and 24</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Relapsed/Refractory Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>ARI0002h</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adult differentiated autologous T-cells from peripheral blood, expanded and transducted with a lentivirus to express a chimeric antigen receptor with anti-BCMA (TNFRSF17) specificity conjugated to the 4-1BB co-stimulatory region and signal-transduction CD3z that has been humanized</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Adult differentiated autologous T-cells with anti-BCMA specificity</intervention_name>
    <description>After pretreatment, adult differentiated autologous T-cells with a chimeric antigen receptor with anti-BCMA specificity will be transfused.</description>
    <arm_group_label>ARI0002h</arm_group_label>
    <other_name>CARTBCMA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients between the age of 18 and 75 years with diagnosis of multiple myeloma

          -  Disease measurable by monoclonal component in serum and/or urine or by free light
             chains in serum according to the eligibility criteria for clinical trials of the
             International Myeloma Working Group

          -  Previous two or more lines of treatment. Patients must have received at least a
             proteasome inhibitor (such as bortezomib or carfilzomib), an immunomodulatory drug
             (lenalidomide or pomalidomide) and an anti-CD38 monoclonal antibody (such as
             daratumumab)

          -  Refractory to the last line of treatment

          -  ECOG functional status ranging from 0 to 2

          -  Life expectancy over 3 months

          -  Patients who, after being informed, give their consent by signing the Informed Consent
             document.

        Exclusion Criteria:

          -  Previous allogeneic transplant in the prior 6 months to inclusion or GVHD that
             requires active systemic immunosuppressive treatment

          -  Absolute lymphocyte count &lt;0.1x10^9/ L

          -  Previous neoplasia, except if patients have been in complete remission &gt; 3 years,
             except for cutaneous carcinoma (non-melanoma)

          -  Active infection that requires treatment

          -  Active infection by HIV, HBV or HCV.

          -  Uncontrolled medical disease

          -  Severe organic condition that meets any of the following criteria: EF &lt;40%, DLCO &lt;40%,
             EGFR &lt;50 ml / min, bilirubin&gt; 3 times normal value (except Gilbert syndrome)

          -  Previous diagnosis of symptomatic AL amyloidosis

          -  Pregnant or lactating women. Women of childbearing age should have a negative
             pregnancy test in the screening phase

          -  Women of childbearing age, including those whose last menstrual cycle was in the year
             prior to screening, who cannot or do not wish to use highly effective contraceptive
             methods from the beginning until the end of the study.

          -  Men who cannot or do not wish to use highly effective contraceptive methods from the
             beginning to the end of the study.

          -  Contraindication to receive conditioning chemotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos Fernandez de Larrea, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinic of Barcelona</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carlos Fernandez de Larrea, MD, PhD</last_name>
    <phone>+34932245400</phone>
    <email>cfernan1@clinic.cat</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sara Varea, BSc</last_name>
    <phone>+34932245400</phone>
    <email>svarea@clinic.cat</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paula Rodr√≠guez Otero, MD, PhD</last_name>
      <email>paurodriguez@unav.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic of Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Fernandez de Larrea, MD PhD</last_name>
      <phone>+34932275400</phone>
      <email>cfernan1@clinic.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Cl√≠nico Universitario Virgen de La Arrixaca</name>
      <address>
        <city>Murcia</city>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose M Moraleda, MD PhD</last_name>
      <email>jmoraled@um.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria V Mateos, MD, PhD</last_name>
      <email>mvmateos@usal.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Del Roc√≠o</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose A Perez-Simon, MD, PhD</last_name>
      <email>josea.perez.simon.sspa@juntadeandalucia.es</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 9, 2020</study_first_submitted>
  <study_first_submitted_qc>March 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2020</study_first_posted>
  <last_update_submitted>July 14, 2020</last_update_submitted>
  <last_update_submitted_qc>July 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Institut d'Investigacions Biom√®diques August Pi i Sunyer</investigator_affiliation>
    <investigator_full_name>Sara V. Latorre</investigator_full_name>
    <investigator_title>Clinical Research Manager</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

